JG
STRO icon

Jefferies Group’s Sutro Biopharma STRO Stock Holding History

Jefferies Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-340
Closed -$50.6K – 1919
2021
Q4 		$50.6K Buy
+340
New +$60.9K ﹤0.01% 1523
2020
Q4 		– Sell
-2,590
Closed -$260K – 1784
2020
Q3 		$260K Buy
+2,590
New +$245K ﹤0.01% 1127

Other funds holding STRO

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Jefferies Group's STRO Position: Q1 2022 in Review

Jefferies Group sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 340 shares — an estimated $50.6K sold.

Jefferies Group first reported a position in STRO in Q3 2020 and held it in 2 quarters. The position peaked at $260K in Q3 2020. 114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

  • Jefferies Group reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 340 Sutro Biopharma shares in Q1 2022, an estimated $50.6K.
  • Jefferies Group first reported a position in Sutro Biopharma in Q3 2020 and held it in 2 quarters.
  • Jefferies Group's Sutro Biopharma position peaked at $260K in Q3 2020.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.